-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally, mostly in the elderly
Chief Physician, Department of Hematology, Jingzhou First People's Hospital
Member of Hubei Provincial Committee of Hematology and Cancer
Member of ESCO Hematology and Oncology Committee
Member of the Hematology Branch of the Asia-Pacific Society of Medical Bioimmunology
Member of the MDS/MPN Branch of the Hematology Committee of the Hubei Medical Bioimmune Society
Member of Jingzhou Hematology Branch
Specialties: Diagnosis and Treatment of Hematological Tumors and Hematopoietic Stem Cell Transplantation
Director of the Department of Hematology, Jingzhou First People's Hospital
Member of Hubei Society of Hematology
Member of the Standing Committee of Hubei Provincial Society of Clinical Oncology
Master tutor of Changjiang University
The first top ten doctors in Jingzhou
Presided over and participated in 5 provincial and municipal scientific research projects, and won 1 third prize of the provincial scientific and technological progress award.
An elderly frail MM patient with renal damage developed peripheral neuropathy (PN) after treatment with bortezomib-based induction regimen.
The full oral IRd regimen containing ixazomib may bring more treatment options for elderly frail MM patients who have received multi-line therapy, further improve the quality of life of patients, and benefit more patients
references
[1] Hervé Avet-Loiseau, et al.
Edit: Moon Reviewer: Janet Typesetting: moly Execution: moly